Mirvetuximab Soravtansine clinical trials
Mirvetuximab Soravtansine is named as an intervention in 10 current clinical trials in our USA, Spain, Belgium, France, Australia, Canada, UK, South Korea, Ireland, China, Germany, Czechia, Italy, Poland, Brazil, Japan, Israel, Denmark, Turkey, India, Sweden, Switzerland, Taiwan and Mexico registers. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is AbbVie (6). The most-studied condition is Ovarian Cancer.
Where Mirvetuximab Soravtansine is approved
All regulators →Of the three regulators tracked here, the first to approve Mirvetuximab Soravtansine was the US, on 14 Nov 2022. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Mirvetuximab Soravtansine patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Mirvetuximab Soravtansine, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- ELAHERE for treatment of ovarian cancer: until 15 Nov 2034. Union Register
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Mirvetuximab Soravtansine
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Mirvetuximab Soravtansine works
All drug targets →- Folate receptor alpha binding agent Binding agentTarget: FOLR1 folate receptor alpha✓ In ChEMBL and the Guide to Pharmacology
- Tubulin inhibitor InhibitorTarget: TubulinChEMBL only
- CancerPhase 3
- Fallopian tube cancerPhase 3
- Fallopian tube carcinomaPhase 3
- Ovarian carcinomaPhase 3
- Primary peritoneal carcinomaPhase 3
- Endometrial cancerPhase 2
- Triple-negative breast carcinomaPhase 2
- Breast cancerPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3545132, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12250, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Mirvetuximab Soravtansine
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Mirvetuximab Soravtansine. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer NICE TA1169 | Recommended | 24 Jun 2026 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Mirvetuximab Soravtansine
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 1 product on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: ElahereEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Mirvetuximab Soravtansine
10 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Mirvetuximab Soravtansine across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
1 single-substance product containing Mirvetuximab Soravtansine on the HPRA medicines list.
- ELAHERE 5 mg/mL concentrate for solution for infusionImmunogen Biopharma (Ireland) Limited · EU/1/24/1866/001
Supply shortages
No entry for Mirvetuximab Soravtansine in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Mirvetuximab Soravtansine
17 conditionsAll 17 conditions
| Condition (as registered) | Trials |
|---|---|
| Ovarian Cancer | 3 |
| Fallopian Tube Cancer | 3 |
| Primary Peritoneal Cancer | 3 |
| Epithelial Ovarian Cancer | 2 |
| Recurrent Ovarian Cancer | 1 |
| Folate Receptor-Alpha Positive | 1 |
| Peritoneal Cancer | 1 |
| High Grade Ovarian Cancer | 1 |
| Advanced High-Grade Epithelial Ovarian Cancer | 1 |
| Fallopian Tube Cancers | 1 |
| Advanced Solid Tumors | 1 |
| Endometrial Cancer | 1 |
| Cholangiocarcinoma | 1 |
| Neoadjuvant | 1 |
| Advanced or Metastatic Pancreatic Adenocarcinoma | 1 |
| Advanced or Metastatic Breast Cancer (BC) | 1 |
| Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AbbVie | 6 |
| AstraZeneca | 1 |
| Pheast Therapeutics | 1 |
| Fudan University | 1 |
| AGO Research GmbH | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Mirvetuximab Soravtansine trials
How many clinical trials are testing Mirvetuximab Soravtansine?
10 current trials in our USA, Spain, Belgium, France, Australia, Canada, UK, South Korea, Ireland, China, Germany, Czechia, Italy, Poland, Brazil, Japan, Israel, Denmark, Turkey, India, Sweden, Switzerland, Taiwan and Mexico registers name Mirvetuximab Soravtansine (also registered as IMGN853) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Mirvetuximab Soravtansine trials recruiting patients?
Yes. 5 of the 10 trials are recruiting: 5 with sites in USA, 3 with sites in Spain, 3 with sites in Belgium, 3 with sites in France, 3 with sites in Australia, 1 with sites in Canada, 2 with sites in UK, 3 with sites in South Korea, 1 with sites in Ireland, 1 with sites in China, 1 with sites in Germany, 2 with sites in Czechia, 1 with sites in Italy, 1 with sites in Poland, 1 with sites in Brazil, 1 with sites in Japan, 1 with sites in Israel, 2 with sites in Denmark, 1 with sites in India, 1 with sites in Sweden, 1 with sites in Switzerland and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Mirvetuximab Soravtansine clinical trials?
AbbVie (6), AstraZeneca (1), Pheast Therapeutics (1) and Fudan University (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Mirvetuximab Soravtansine clinical trials in Ireland?
Yes. 3 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Mirvetuximab Soravtansine licensed in Ireland?
Yes. The HPRA medicines list includes 1 single-substance product containing Mirvetuximab Soravtansine, for example ELAHERE 5 mg/mL concentrate for solution for infusion (Immunogen Biopharma (Ireland) Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Mirvetuximab Soravtansine shortage?
Not in the lists we track: Mirvetuximab Soravtansine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mirvetuximab Soravtansine works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mirvetuximab Soravtansine works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mirvetuximab Soravtansine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.